Association between polymorphisms of ACE, B2AR, ANP and ENOS and cardiovascular diseases: a community-based study in the Matsu area
-
Chaur-Jong Hu
Abstract
Background: Cardiovascular diseases (CVDs) are the leading cause of death in most countries of the world. In this study, associations between CVDs and polymorphisms of angiotensin-converting enzyme (ACE), atrial natriuretic peptide (ANP), β2-adrenal receptor (B2AR) and endothelial nitric oxide synthase (ENOS) genes were explored in a community-based setting.
Methods: Between March and May 2001, 1740 subjects ≥35 years from the Matsu area in Taiwan were recruited to this study, representing 71.6% of the target population in Matsu. After informed consent was obtained during an interview, physical examination, resting ECG, serum biochemical profile and a questionnaire survey were used to obtain information. Genomic DNA was also collected and analyzed. Owing to technical limitations, 1186 samples were analyzed. Genetic polymorphisms of the genes in question were investigated using PCR and restriction fragment length polymorphism (RFLP). The distribution of allele frequencies for these genes was derived for stroke, coronary artery disease, hypertension, diabetes, hypercholesterolemia, hypertriglyceridemia and overweight subgroups.
Results: The ENOS Glu298Asp polymorphism was associated with hypercholesterolemia (odds ratio 0.658, 95%CI 0.460–0.940; p=0.025) and the ACE D/I variant was associated with hypertriglyceridemia (odds ratio 0.722, 95%CI 0.536–0.973; p=0.033). Polymorphisms of the other genes were not associated with any of the disease groups.
Conclusions: This community-based study reveals that genetic factors might play a role in the metabolism of lipids. The genetic risk for CVDs needs further investigation.
Clin Chem Lab Med 2007;45:20–5.
References
1. Sacco RL, Boden-Albala B. Stroke risk factors: identification and modification. In: Fisher M, editor. Stroke therapy, 2nd ed. Oxford: Butterworth-Heinemann, 2001.Search in Google Scholar
2. Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet2004;5:189–218.10.1146/annurev.genom.5.061903.175930Search in Google Scholar
3. Herrmann SM, Paul M. Studying genotype-phenotype relationships: cardiovascular disease as an example. J Mol Med2002;80:282–9.10.1007/s00109-002-0330-xSearch in Google Scholar
4. Website of Lien-Chiang County: www.matsu.gov.tw.Search in Google Scholar
5. O'Malley JP, Maslen CL, Illingworth DR. Angiotensin-converting enzyme and cardiovascular disease risk. Curr Opin Lipidol1999;10:407–15.10.1097/00041433-199910000-00005Search in Google Scholar
6. Kato N, Sugiyama T, Morita H, Nabika T, Kurihara H, Yamori Y, et al. Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. Clin Sci2000;98:251–8.10.1042/CS19990220Search in Google Scholar
7. Bray MS, Krushkal J, Li L, Ferrell R, Kardia S, Sing CF, et al. Positional genomic analysis identifies the β2-adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation2000;101:2877–82.10.1161/01.CIR.101.25.2877Search in Google Scholar
8. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension1998;32:3–8.10.1161/01.HYP.32.1.3Search in Google Scholar
9. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res1992;20:1433.10.1093/nar/20.6.1433-aSearch in Google Scholar
10. Lee Y, Lin RS, Sung FC, Yang C, Chien K, Chen W, et al. Chin-Shan Community Cardiovascular Cohort in Taiwan – baseline data and five-year follow-up morbidity and mortality. J Clin Epidemiol2000;53:838–46.10.1016/S0895-4356(00)00198-0Search in Google Scholar
11. Levenson JW, Skerrett PJ, Gaziano JM. Reducing the global burden of cardiovascular disease: the role of risk factors. Prev Cardiol2002;5:188–99.10.1111/j.1520-037X.2002.00564.xSearch in Google Scholar
12. Ezzati M, Hoorn SV, Rodgers A, Lopez AD, Mathers CD, Murray CJ. Comparative Risk Assessment Collaborating Group. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet2003;362:271–80.10.1016/S0140-6736(03)13968-2Search in Google Scholar
13. Niu T, Chen X, Xu X. Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications. Drugs 2002;62:977–93.10.2165/00003495-200262070-00001Search in Google Scholar
14. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest1990;86:1343–6.10.1172/JCI114844Search in Google Scholar
15. del Ser T, Bornstein B, Barba R, Cemillan C. Relationship of angiotensin converting enzyme genotype with serum triglyceride concentration in stroke patients. Neurosci Lett2001;316:21–4.10.1016/S0304-3940(01)02345-XSearch in Google Scholar
16. Prisco D, Fatini C, Battaglini B, Gensini F, Fedi S, Falai M, et al. Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients. Int J Clin Lab Res2000;30:179–85.10.1007/s005990070004Search in Google Scholar
17. Byberg L, Siegbahn A, Berglund L, McKeigue P, Reneland R, Lithell H. Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. Arterioscler Thromb Vasc Biol1998;18:258–64.10.1161/01.ATV.18.2.258Search in Google Scholar
18. Radomski MW, Salas E. Nitric oxide − biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. Atherosclerosis1995;118(Suppl):S69–80.10.1016/0021-9150(95)90075-6Search in Google Scholar
19. Dimmeler S, Zeiher AM. Nitric oxide – an endothelial cell survival factor. Cell Death Differ1999;6:964–8.10.1038/sj.cdd.4400581Search in Google Scholar PubMed
20. McDonald DM, Alp NJ, Channon KM. Functional comparison of the endothelial nitric oxide synthase Glu298Asp polymorphic variants in human endothelial cells. Pharmacogenetics2004;14:831–9.10.1097/00008571-200412000-00006Search in Google Scholar PubMed
21. Paradossi U, Ciofini E, Clerico A, Botto N, Biagini A, Colombo MG. Endothelial function and carotid intima-media thickness in young healthy subjects among endothelial nitric oxide synthase Glu298→Asp and T–786→C polymorphisms. Stroke2004;35:1305–9.10.1161/01.STR.0000126482.86708.37Search in Google Scholar PubMed
22. Hoffmann IS, Tavares-Mordwinkin R, Castejon AM, Alfieri AB, Cubeddu LX. Endothelial nitric oxide synthase polymorphism, nitric oxide production, salt sensitivity and cardiovascular risk factors in Hispanics. J Hum Hypertens2005;19:233–40.10.1038/sj.jhh.1001801Search in Google Scholar PubMed
23. Rohrer DK, Chruscinski A, Schauble EH, Bernstein D, Kobilka BK. Cardiovascular and metabolic alterations in mice lacking both β1- and β2-adrenergic receptors. J Biol Chem1999;274:16701–8.10.1074/jbc.274.24.16701Search in Google Scholar PubMed
24. Huang G, Xing H, Hao K, Peng S, Wu D, Guang W, et al. β2 adrenergic receptor gene Arg16Gly polymorphism is associated with therapeutic efficacy of benazepril on essential hypertension in Chinese. Clin Exp Hypertens2004;26:581–92.10.1081/CEH-200031839Search in Google Scholar
25. Lang RE, Unger T, Ganten D. Atrial natriuretic peptide: a new factor in blood pressure control. J Hypertens1987;5:255–71.10.1097/00004872-198706000-00001Search in Google Scholar PubMed
26. Rubattu S, Ridker P, Stampfer MJ, Volpe M, Hennekens CH, Lindpaintner K. The gene encoding atrial natriuretic peptide and the risk of human stroke. Circulation1999;100:1722–6.10.1161/01.CIR.100.16.1722Search in Google Scholar PubMed
27. Lin YC, Chang YM, Yu JM, Yen JH, Chang JG, Hu CJ. Toll-like receptor 4 gene C119A but not Asp299Gly polymorphism is associated with ischemic stroke among ethnic Chinese in Taiwan. Atherosclerosis2005;180:305–9.10.1016/j.atherosclerosis.2004.12.022Search in Google Scholar PubMed
28. Hassan A, Ali N, Dong Y, Carter ND, Markus HS. Atrial natriuretic peptide gene G664A polymorphism and the risk of ischemic cerebrovascular disease. Neurology2001;57:1726–8.10.1212/WNL.57.9.1726Search in Google Scholar
©2007 by Walter de Gruyter Berlin New York
Articles in the same Issue
- CCLM: Bringing advances in laboratory medicine to the “New World”
- Diagnostic approach to inherited bleeding disorders
- Linking laboratory and medication data: new opportunities for pharmacoepidemiological research
- Association between polymorphisms of ACE, B2AR, ANP and ENOS and cardiovascular diseases: a community-based study in the Matsu area
- Anti-thyroid-stimulating hormone receptor antibodies determined by second-generation assay
- Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients
- Surrogate markers of insulin resistance in assessing individuals with new categories “prehypertension” and “prediabetes”
- Evaluation of pre-analytical, demographic, behavioural and metabolic variables on fibrinolysis and haemostasis activation markers utilised to assess hypercoagulability
- Hyperhomocysteinaemia and immune activation in patients with cancer
- The effect of homocysteine reduction by B-vitamin supplementation on inflammatory markers
- Lipid peroxidation in Down syndrome caused by regular trisomy 21, trisomy 21 by Robertsonian translocation and mosaic trisomy 21
- Pregnancy-associated plasma protein A in dialysis patients
- L-Cysteine supplementation prevents exercise-induced alterations in human erythrocyte membrane acetylcholinesterase and Na+,K+-ATPase activities
- Assessment of homocysteine, neopterin and nitric oxide levels in Behcet's disease
- Increased adenosine deaminase in hydatidiform mole
- Classification tree analysis for the discrimination of pleural exudates and transudates
- External quality assessment of hemoglobin A2 measurement: data from an Italian pilot study with fresh whole blood samples and commercial HPLC systems
- Comparison of four commercial quantitative HIV-1 assays for viral load monitoring in clinical daily routine
- Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: an update
- Analytical validation of the new version of the Liaison N-Tact PTH assay
- Validation of an automated sensitive immunoassay for quantitation of cytokines in the sputum of cystic fibrosis patients
- Strong interference of hemoglobin concentration on CSF total protein measurement using the trichloroacetic acid precipitation method
- Correction of patient results for Beckman Coulter LX-20 assays affected by interference due to hemoglobin, bilirubin or lipids: a practical approach
- Acquiring a measurement system within the framework of standard ISO 15189
- Six Sigma and laboratory consultation
- ESR or LSRB, that is the question!
- Reply to the Letter written by Hardeman
- Natriuretic peptides. The hormones of the heart
Articles in the same Issue
- CCLM: Bringing advances in laboratory medicine to the “New World”
- Diagnostic approach to inherited bleeding disorders
- Linking laboratory and medication data: new opportunities for pharmacoepidemiological research
- Association between polymorphisms of ACE, B2AR, ANP and ENOS and cardiovascular diseases: a community-based study in the Matsu area
- Anti-thyroid-stimulating hormone receptor antibodies determined by second-generation assay
- Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients
- Surrogate markers of insulin resistance in assessing individuals with new categories “prehypertension” and “prediabetes”
- Evaluation of pre-analytical, demographic, behavioural and metabolic variables on fibrinolysis and haemostasis activation markers utilised to assess hypercoagulability
- Hyperhomocysteinaemia and immune activation in patients with cancer
- The effect of homocysteine reduction by B-vitamin supplementation on inflammatory markers
- Lipid peroxidation in Down syndrome caused by regular trisomy 21, trisomy 21 by Robertsonian translocation and mosaic trisomy 21
- Pregnancy-associated plasma protein A in dialysis patients
- L-Cysteine supplementation prevents exercise-induced alterations in human erythrocyte membrane acetylcholinesterase and Na+,K+-ATPase activities
- Assessment of homocysteine, neopterin and nitric oxide levels in Behcet's disease
- Increased adenosine deaminase in hydatidiform mole
- Classification tree analysis for the discrimination of pleural exudates and transudates
- External quality assessment of hemoglobin A2 measurement: data from an Italian pilot study with fresh whole blood samples and commercial HPLC systems
- Comparison of four commercial quantitative HIV-1 assays for viral load monitoring in clinical daily routine
- Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: an update
- Analytical validation of the new version of the Liaison N-Tact PTH assay
- Validation of an automated sensitive immunoassay for quantitation of cytokines in the sputum of cystic fibrosis patients
- Strong interference of hemoglobin concentration on CSF total protein measurement using the trichloroacetic acid precipitation method
- Correction of patient results for Beckman Coulter LX-20 assays affected by interference due to hemoglobin, bilirubin or lipids: a practical approach
- Acquiring a measurement system within the framework of standard ISO 15189
- Six Sigma and laboratory consultation
- ESR or LSRB, that is the question!
- Reply to the Letter written by Hardeman
- Natriuretic peptides. The hormones of the heart
